SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Matritech (NASDAQ - NMPS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gary Schneekloth who wrote (305)11/9/1996 5:03:00 PM
From: Damon Pham   of 849
 
They appear to be moving in the right direction. The revenue-expense gap is narrowing. However, the next couple of quarters will be the real test. If their product is embraced by the market in the US and Europe, the revenues should soar. Profits could be several quarters away still though since they are still incurring heavy costs associated with ongoing R&D and clinical tests.

This is a stock that you should buy if you have a long-term perspective. It has had a massive runup this year already so I'm not surprised to see it give back some of this back in the absence of any major news impacting the company positively. Don't be surprised though if this stock moves back up just as quickly as it has fallen the past couple of weeks when they announce some good news on the status of their clinical tests.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News